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Signs and symptoms of endocrine dysfunction related to adrenal nodules usually are 
linked to their specific hormonal hypersecretion. Still, these diagnoses are not always a 
straightforward process and there have been cases in which the clinical expression has 
been discordant with the tumour histologic features.  
A 59-year-old woman was observed at the endocrinology outpatient department due to 
uncontrolled diabetes mellitus. Furthermore, the patient referred paroxysmal high blood 
pressure and weight loss. Her medical history was remarkable by uncontrolled 
hypertension, chronic hepatitis C, past pelvic actinomycosis and an adrenal nodule 
diagnosed due to an unrelated purpose. Endocrine evaluation showed serum morning 
cortisol, urinary cortisol and metanephrines within the reference range, but supressed 
adrenocorticotropic hormone (ACTH), loss of cortisol circadian rhythm and a non-
suppression in the dexamethasone test, suggesting the diagnosis of Cushing’s syndrome. 
The imaging procedures were inconclusive. The CT scan revealed a lesion of 20 mm in 
the left adrenal with a spontaneous density of 33 HU, well-defined contours, a relative 
wash-out of 61%, and 120HU on portal venous phase. The MRI showed a hyperintense 
nodule in T1-weighted images, without a signal dropout in out-of-phase T1 imaging. 
There was no evidence of tumour invasion of adjacent tissues, ganglion or distant 
metastasis. MIBG scintigraphy did not show abnormal findings.  
The patient underwent unilateral left adrenalectomy. Histopathologic examination 
showed an adenoma with foci of oncocytic cells and neuromelanin pigments. The surgical 
procedure resulted in Cushing’s syndrome remission, and an improvement in blood 
pressure and glucose control.  
This medical report illustrates the difficulties in the differential diagnosis of an adrenal 
adenoma. The patient presented some clinical features suggestive of pheochromocytoma, 
while the typical clinical findings of a Cushing syndrome were absent. Nevertheless, she 
presented a history of diabetes mellitus, hypertension, chronic hepatitis C and 
actinomycosis, for which the Cushing Syndrome might have contributed. Additionally, 
the atypical imaging findings made the differential diagnosis more complicated, when it 
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Resumo 
Uma das disfunções da glândula supra-renal é a síndrome de Cushing, podendo ser 
causada por um tumor benigno ou maligno. Contudo, alguns dos diagnósticos clínicos 
podem ser autênticos quebra-cabeças.  
Uma mulher de 59 anos foi observada na Consulta Externa de Endocrinologia por 
diabetes melitus descompensada. Adicionalmente, a doente referia episódios paroxísticos 
de pressão arterial elevada e emagrecimento. Nos seus antecedentes pessoais, 
destacavam-se os diagnósticos um nódulo da supra-renal, hipertensão arterial mal 
controlada, hepatite C crónica e actinomicose pélvica. 
A avaliação endócrina subsequente revelou valores séricos de metanefrinas, de cortisol 
sérico e urinário dentro dos parâmetros de referência. Contudo, o valor sérico da ACTH 
encontrava-se suprimido, registou-se perda do ritmo circadiano do cortisol e o teste de 
supressão pela dexametasona revelou uma não-supressão do cortisol, sugerindo o 
diagnóstico de síndrome de Cushing.  
Os exames imagiológicos revelaram-se inconclusivos relativamente à natureza da lesão: 
a TC mostrou uma lesão de 20 mm na supra-renal esquerda com densidade espontânea 
de 33HU, com contornos bem-definidos, um washout relativo de 61% e densidade de 
120HU na fase portal venosa. A ressonância magnética nuclear revelou um nodulo 
hiperintenso em T1, sem sinal após contraste, sem evidencia de invasão tumoral de 
tecidos adjacentes, nem adenopatias ou metástases à distância. Foi também realizada uma 
cintigrafia com MIBG que não revelou alterações.  
A doente foi submetida a uma adrenalectomia esquerda. A análise histopatológica revelou 
um adenoma com focos de células oncocíticas e pigmentos de neuromelanina. O 
procedimento cirúrgico resultou numa remissão da síndrome de Cushing e redução da 
pressão arterial e dos níveis glicémicos.  
Este caso medico ilustra as dificuldades no diagnóstico diferencial de um adenoma da 
supra-renal. A doente apresentava alguns sintomas sugestivos de feocromocitoma e não 
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apresentava os sintomas e sinais típicos de uma Síndrome de Cushing. Contudo, 
apresentava diabetes melitus, hipertensão, hepatite C crónica e história prévia de 
actinomicose pélvica para os quais a Síndrome de Cushing poderá ter contribuído. Os 
exames imagiológicos também não foram esclarecedores, quando de facto se tratava de 
um adenoma preto da supra-renal com uma histologia muito peculiar.  
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An adrenal incidentaloma is the designation of a clinically silent adrenal mass, discovered 
accidentally during imaging procedures [1]. Due to the greater availability of imaging 
procedures and exams, adrenal incidentalomas are increasing in frequency in the clinical 
practice [2]. They can be subdivided according to their aetiology: an adenoma is the most 
common type of adrenal tumour and it is usually non-functioning. However, 5-47% may 
secrete cortisol and 1.6-3.3% secrete mineralocorticoids [3]. More rare diagnosis can also 
be made, including pheochromocytoma, adrenocortical carcinoma and metastatic cancer 
[3].  
The management of a patient with an adrenal adenoma includes clinical and laboratorial 
search for symptoms and signs of adrenal hormone excess and the assessment of the risk 
of malignancy through imaging procedures [4].   
As previously reported, adrenal adenomas can be responsible for symptoms and signs 
related to hormonal excess, e.g., pheochromocytoma, Conn’s or Cushing’s syndrome. 
The symptoms depend mostly on the main compound secreted by the lesion [5]. Cushing 
syndrome is the most common presentation in functioning adenomas, being ACTH-
independent, and consisting of a constellation of symptoms and signs secondary to 
prolonged exposure to elevated cortisol levels. Cortisol secretion from adrenal adenomas 
are responsible for 15-20% of all Cushing syndromes. These functional adenomas are 
most common in the fourth and fifth decades and females are more likely to be affected 
[6]. Nevertheless, more rarely, pheochromocytomas are also capable of secreting various 
hormones, including ACTH, and Cushing’s syndrome has been reported in the literature 
secondary to this type of tumour. 
The laboratorial assessment includes a screening for Cushing syndrome with an overnight 
(1 mg) dexamethasone suppression test, screening for pheochromocytoma with 
fractionated plasma metanephrines and screening for hyperaldosteronism measuring the 
ratio of plasma aldosterone to plasma renin if the patient has concomitant hypertension 
or unexplained hypokaliema. If there is a possibility of adrenocortical carcinoma, sex-
hormones and steroids precursors should be measured as well. In parallel, a non-contrast 
CT should be done initially. If the results are uncertain, washout CT, chemical shift MRI 
and FDG-PET should  be considered [4].  
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If an adrenal mass is responsible for hormonal excess or has radiological findings 
suspicious of malignancy, adrenalectomy is the standard treatment [4]. 
After surgery, the histopathological examination of the mass is one of foremost 
importance for the diagnosis, discerning malignity. The Weiss scoring system is the most 
common evaluating approach. However, this system has its limitations and may not be 
applicable so easily in tumours with uncommon histopathology, such as a tumour with 
oncocytic characteristics [7]. 
Therefore, some adrenal tumours can represent a diagnostic challenge. Herein, we report 














A 66-years-old caucasian woman was observed at the endocrinology outpatient 
department due to uncontrolled Diabetes Mellitus. The patient had the diagnosis of 
Diabetes Mellitus from the age of 53, with diabetic retinopathy treated with 
photocoagulation. Her medical records were also noteworthy of a chronic hepatitis C 
diagnosed at the age of 30 treated with interferon without cure. She also had a past pelvic 
actinomycosis infection with resection of two thirds of the rectum, colostomy and 
salpingo-oophorectomy at the age of 50, and a history of a fibromyoma treated by 
hysterectomy at 53.  
In terms of symptomatology, the patient referred paroxysmal hypertension episodes 
(approximately one per week), followed by a “heat feeling in the mouth” and tremors. 
Additionally, the patient referred to a feeling of sadness and crying spells.. The patient 
also referred asthenia and an unexplained and poorly specified weight loss during the last 
years before her appointment in the outpatient clinic. She also had a record of a 15 mm 
adrenal mass discovered at the age of 55 in a context that the patient does not know of, 
nor the reason for this imaging procedure. The clinical examination revealed a patient 
with 49 kg, 1.62m and a BMI of 18.7 Kg/m2. The blood pressure laying down indicated 
167/85mmHg and a heart rate of 100 bpm, measured in the left arm. In an orthostatic 
position, after 1-minute standing, the values were similar. She presented general muscle 
weakness. Physical examination was otherwise unremarkable, namely there was no 
evidence of tremor, cardiac arrhythmia, fever, diaphoresis, virilization, striae, 
ecchymoses, buffalo-hump fat distribution, gynecomastia, any palpable mass in the 
abdomen or adenomegaly.  
She was medicated daily with 100 mg of sitagliptin per day, 825 mg of metformin three 
times per day, 14 international units (IU) of detemir insulin at breakfast and 7 IU at 
supper, 10 mg of sinvastatin per day, 10 mg of perindopril per day, 2.5 mg of indapamide 
per day, 5 mg of amlodipine and 5 mg of bisoprolol per day. Even with this medication, 
hemoglobin A1c (HbA1c) was around 10-12% and blood pressure values around 
160/80mmHg.  
Her laboratorial work-up, performed under nifedipine and insulin therapy (see table 1) 
showed a supressed ACTH, 24 h urinary cortisol levels slightly elevated, normal morning 
serum cortisol values with abolishment of its circadian rhythm, and no suppression after 
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the administration of 1 mg de dexamethasone (23 mcg/dL). Catecholamine 24h urine 
testing was completed showing normal values except for a raised value of epinephrine. 
The clonidine suppression test was then made, which showed normal levels of 
catecholamines, both baseline and after clonidine administration.   
The EKG and chest x-ray were normal. The 24-hours ambulatory blood pressure 
monitoring (under nifedipine 30mg per day) revealed mild systolic diurnal and nocturnal 
hypertension, with non-dipper pattern, without spikes evocative of pheochromocytoma 
(table 2). 
The computed tomography showed a thickening of the left adrenal gland, with a nodule 
of 20 mm with an attenuation of 33 HU and well-defined contours. It had a relative 
washout of 61% and a gain of absolute contrast in the portal phase of 120HU. The MRI 
showed a 20-mm nodule in the left adrenal gland, with a discrete hyperintensity regarding 
the adjacent adrenal parenchyma in T1-weighted images, without a signal dropout in out-
of-phase T1 imaging. The imaging procedures did not reveal any organ invasion or 
metastasis. MIBG scintigraphy did not show abnormal findings. 
With the clinical features, biochemical evidence of hypercortisolism and normal 
catecholamines, she was diagnosed to have a functioning left adrenal tumour with 
Cushing syndrome.  
The patient was submitted to laparoscopic left adrenalectomy. In the surgery, the mass 
was confined to the left adrenal gland. Preoperative medical management for 
pheochromocytoma was made with 0.9 % sodium chloride solution, doxazosin 12mg per 
day and propranolol 40 mg 8/8h. No intraoperative hemodynamic fluctuations were noted 
during anaesthesia and surgery, and the postoperative period was uneventful, medicated 
with nifedipine 60 mg per day.  
Histopathological examination revealed an adrenal gland with 3.2x1.7x1.7 cm, with a 
well-demarcated and capsulated nodule in the cranial pole of the gland, with 1.9x1.5 cm 
of dimension, of brown colour with yellow spots. Adrenal tissue was identified grossly 
around it.  Light microscopic examination of H&E-stained sections revealed an adrenal 
cortical adenoma with oncocytic cell foci and extended areas where cells showed an 
abundant brown pigment in the cytoplasm, compatible with neuromelanin – black 
adenoma.   
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After the surgery, she did oral cortisol replacing treatment (hydrocortisone), in 
progressively lower doses, during the next 8 months. Six months after surgery she 
presented a morning cortisol level of 1µg/dL. Between 8 months after the surgery and 1 
year and two months, adrenal function was apparently restored, as evidenced by a 
morning serum cortisol level of 15µg/dL one year after surgery and 22 μg/dL one year 
and to months after surgery (and she also presented a normal suppression by 1mg 
dexamethasone). Even though adrenal function could have been apparently restored, she 
complained of lack of strength when glucocorticoid replacement was withdrawn, and 
therefore, she returned to take hydrocortisone 10 mg in alternate days, until 18 months 
after surgery.  
One month after surgery, in the endocrinology follow-up appointment, the patient 
revealed not only an improvement of the hypertension control, having a mean blood 
pressure value of 115/65, heart rate of 80 bpm, having reduced her antihypertensive 
medication (eliminating amlodipine, maintaining only telmisartan 
80mg/hydrochlorothiazide 25mg). Control of diabetes mellitus was also significantly 
improved, she had progressively lower glycemia values comparatively to the values 
before surgery (hemoglobin A1c of 7,4%, and random plasma glucose between 120-160 
mg/dL), taking a unique dosage of 24 IU of glargine insulin at breakfast one month after 
the surgery and complete elimination of insulin after two months. Approximately 4 
months after the surgery, the patient had gained 2kg of body weight and 9 kg after four 
years.  
The patient was also followed up by a gastroenterologist in the outpatient department due 
to chronic hepatitis C. The patient was treated with interferon for several years without 
response, and the infection was only eradicated in 2016 after taking sofosbuvir and 






In this study we report a left laparoscopic adrenalectomy performed for a tumour with 
some findings suggestive of pheochromocytoma and laboratory findings of subclinical 
Cushing syndrome which, however, had histopathologic features of an adrenal black 
adenoma.  
Hereby, we describe a patient with an adrenal nodule, detected in an imaging procedure 
performed for un unrelated purpose [3]. Due to the increasingly availability of imaging 
for diagnostic or treatment aims, incidentalomas are becoming more and more frequent, 
however, the majority of the studies are retrospective resulting from autopsy or radiology, 
having referral bias, unsatisfactory clinical information, and multiple patient selection 
criteria [2]. Cortical adenomas are the most common entities in this diagnosis (up to 80% 
all masses) [8, 9]. Even though the majority of cortical tumours are non-functioning, 5-
47% secrete cortisol and 1.6-3.3% secrete mineralocorticoids. [3]. Other causes include 
cortical carcinomas accounting with 1.4% of the cases of adrenal masses or medullar 
tumours such as pheochromocytoma accounting for 1.8-4.3% [10, 11]. The reported 
frequencies differ, depending on the study and its criteria. There is, however, clear 
evidence that the vast majority of adrenal incidentalomas are benign adrenocortical 
adenomas. [4]  
So, in the initial work-up of an incidentaloma, it is relevant and likely decisive to 
distinguish between a benign and malignant lesion, its origin - derived from the adrenal 
cortex, the medulla or metastatic - as well as differentiate if the mass is functioning or 
non-functioning. [4] Malignant lesions may need expeditious surgical intervention and/or 
some other therapies, therefore, any delay should be avoided. 
Concerning their origin, if the mass is medullar, it should be differentiated in 
pheochromocytoma (benign or malignant), ganglioneuroma, neuroblastoma, or 
ganglioneuroblastoma. [11] If cortical, these can arise from the three zones (zona 
glomerulosa, zona fasciculata and zona reticularis). If the lesion is functional, it can result 
in a hormonal hypersecretion (mineralocorticoids, glucorticoids, sexual steroids and 
catecholamines) with its associated respective clinical syndromes (Conn syndrome, 
Cushing syndrome, adrenal hyperandrogenism, pheochromocytoma). [12]  
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According to the recommended guidelines from the European Society of Endocrinology, 
there should be an assessment of hormone excess and of the risk of malignancy through 
clinical history, physical examination, measurement of hormone levels by biochemical 
testing and imaging procedures [4]. For pheochromocytoma and paraganglioma, genetic 
testing can also be necessary, in particular patients with suspected germline mutations 
[13]. 
Thus, clinical history and physical examination should be guided towards the symptoms 
and signs related to hormonal secretion and malignant disease [4]. In this case, the patient 
presented symptoms compatible with pheochromocytoma, such as headache, diaphoresis, 
palpitation, tachycardia, anxiety episodes and weight loss, with onset 5 years before the 
incidentaloma diagnosis. However, she also demonstrated clinical comorbidities which 
could be associated with Cushing syndrome, such as medical history depression, hepatitis 
C, actinomycosis, Diabetes Mellitus, insulin resistance and hypertension are suggestive 
of both clinical situations. Although the presence of paroxysmal episodes are suggestive 
of pheochromocytoma, those episodes were not confirmed by the ambulatory blood 
pressure monitoring, showing nevertheless, high blood pressure . [14]  
Secondly, after the initial clinical history and physical examination, hormonal assessment 
is critical in the work-up for an adrenal lesion. Concerning the differential diagnosis, for 
the initial testing of our patient must include the screening of Cushing syndrome, with 
tests that measure excessive glucocorticoid levels; and concerning pheochromocytoma, 
measuring plasma free metanephrines or urinary fractionated metanephrines. Based on 
such reasoning, levels our patient of 24h-urinary cortisol level was slightly increased. 
Although the morning cortisol level was within normal range, ACTH was supressed. 
Concerning catecholamines, urinary 24h samples showed slightly raised epinephrine. The 
other values such as urinary metanephrines and normetanephrines were normal. 
The patient underwent a 1 mg overnight dexamethasone suppression test, which has a 90-
96% sensitivity [15]. The latter has a 30% false-positive rate, more often in patients with 
obesity, chronic illness, psychiatric disorders, and alcohol abuse [16].  Therefore, this test 
cannot give a diagnosis of Cushing syndrome with certainty, and supplementary tests are 
thus necessary, such as measurement late-night salivary cortisol test (sensitivity of 90-
96%, specificity > 90%) or 24-hour urine free cortisol (sensitivity of 90-98%, specificity 
90%) [15, 17-19]. It should be noted that there is a substantial heterogeneity in the 
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specificity and sensibility between the studies according to differences in diagnostic 
protocols and definitions of outcome. Some authors advocated that they should be used 
in concert to complement each other and two of them should be done simultaneously, 
even though the European guidelines advise for the 1mg overnight dexamethasone 
suppression test as the first test.  
In order to rule out false-positive and negative responses, some authors suggest the 
measurement of both cortisol and dexamethasone to ensure satisfactory plasma 
dexamethasone concentrations [>5.6 nmol/liter (0.22 μg/dl)].[20]  Additionally, several 
studies have used a cortisol cut-off value between 50 and 138 nmol/L (1.8–5.0 μg/dL) in 
the 1-mg DST to insure the diagnosis of ‘autonomous cortisol secretion’, expanding the 
sensitivity to 100%. If the values are <1.8, the diagnosis of this syndrome is unlikely. The 
patient had a supressed ACTH, even if the baseline morning cortisol level was within 
normal range. Moreover, the normal circadian rhythm of cortisol was lost, and the cortisol 
levels were not supressed in the dexamethasone test. Besides, the 24h urinary cortisol was 
high, corroborating the Cushing syndrome by hormonal functioning adrenal mass. [21, 
22]. The patient did not present the typical classic signs of this syndrome, as mentioned 
previously, but the reported prevalence of subclinical Cushing's syndrome among patients 
with adrenal incidentaloma is not rare, ranging from 5% to 20% [23-26].   
Low age-and-gender–adjusted DHEAS levels are found in Cushing’s syndrome due to 
adrenal adenoma, even though that it not fully understood, whereas DHEAS levels are a 
marker of adrenal androgen excess and may signal an adrenal carcinoma. In this patient, 
DHEAS levels were low, therefore, by itself, not suggesting a malignant lesion. Part of 
the explanation comes from the fact that many of the steroid biosynthesis enzymes are 
defective in adrenocortical carcinomas, having therefore an inefficient steroid production, 
increasing plasma level patterns of steroid precursors. However, the sensitivity and 
specificity of this parameter are low (51% and 65%, respectively [27].The studies relating 
to DHEAS and adrenal carcinomas are still very uneven and heterogeneous, limiting its 
practical applicability and therefore, a normal value will not exclude a carcinoma and 
further tests will be necessary [28, 29]. 
The presence of hypertension in Cushing syndrome is about 80% [30]. The cortisol 
related contributing factors to hypertension seem to result from the interaction between 
numerous pathophysiological mechanisms modifying plasma volume, cardiac output and 
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peripheral vascular resistance and pressor response to angiotensin II, all increased in this 
syndrome. Besides this, studies have shown that cortisol in excess can bind to 
mineralocorticoid receptors, thus mimic an excess of aldosterone. There is also a decrease 
of nitric oxide, enhanced vasoconstriction and reduced vasodilatation by increased levels 
of endotelin-1 [31, 32]. Concerning glucose metabolism, cortisol in excess seems to 
contribute as well to inhibit insulin secretion and sensitivity, glucose uptake and glycogen 
synthesis, therefore resulting in insulin resistance and Diabetes Mellitus. [33-37]  
Concerning primary aldosteronism, aldosterone/renin ratio as well as measurement of 
plasma potassium, should be made in patients with high blood pressure or  unexplained 
hypokalemia [38]. Both were normal in the patient.  
Urinary fractionated metanephrines were measured and were within the reference range. 
This analysis has a sensitivity of 85-100%. So, even though the patient had hypertension, 
fractionated metanephrines were within the normal reference range, against the possible 
diagnosis of a pheochromocytoma.  
Concerning imaging procedures, although most adrenal incidentalomas are benign 
adenomas, the morphological characteristics by itself cannot consistently differentiate 
between an adenoma and a malignant lesion. [39, 40] Following the ESE guidelines, it is 
recommend that all patients with adrenal incidentalomas should undergo a non-contrast 
CT to ascertain that the mass is homogeneous, lipid-rich and consequently benign. [4]. 
The attenuation value in unenhanced CT, with a cut-off of <10 HU, expressed in 
Hounsfield Units (HU), can be used to differentiate between an adenoma and other 
abnormalities[41] calculating the likelihood of being an adenoma. This method has more 
than 97% of sensitivity [42].  Nevertheless, we cannot forget the fact that 30% of all 
adenomas are lipid-poor and can be indistinguishable of a carcinoma in an unenhanced 
CT. [43] If that is the case, the percentage of change in the washout of the contrast 
material on the dynamic and delayed contrast-enhanced CT can be a good method to 
distinguish. [44, 45] These suggestions are based on the remark that adrenal adenomas 
display faster and superior washout of the contrast material than adrenal nonadenomas. 
>40% relative washout is highly suggestive of adrenal adenoma [46]. Typically, 
adenomas lose their contrast more quickly than nonadenomas (assessment 15 minutes 
after the administration of the contrast), such as malignant lesions that have abnormal 
vasculature, and therefore, a higher microvascular density, show slower blood flow and 
16 
 
abnormal endothelial permeability. Consequently, the contrast material is accumulated 
within the tissue a longer time. In our patient’s case, the CT scan showed a lesion of 20 
mm, spontaneous density of 33 HU, well-defined contours and a relative wash-out of 
61%. Pheochromocytomas, for example, may exhibit a high percentage washout on 
delayed images, but they typically enhance to a greater degree than adenomas do on portal 
phase images.[47]  Therefore, the CT scan is not clear in the definition of a benign or 
malignant mass, having still the possibility of being a pheochromocytoma.  
The MRI imaging may be important to make a diagnosis in some cases, particularly when 
the CT scan results are ambiguous. The most characteristic feature of an adrenal adenoma 
is the presence of intracellular lipid, in which chemical shift imaging is the most reliable 
technique for its diagnosis [48]. Most adrenal adenomas demonstrate a loss of signal 
intensity on out-of-phase images. The loss of the signal intensity on opposed-phase 
images relative to the spleen is indicative of the presence of intracytoplasmic lipids and 
therefore is diagnostic of adenoma [49]. Concerning pheochromocytoma, T2-weighted 
sequences are more specific than CT and infrequently lose signal in out-of-phase [49]. 
The patient did not present this loss of signal in the left adrenal gland and presented 
hyperintensity in T1, and so, it is not in complete favour of an adenoma nor 
pheochromocytoma.  
If, in one hand, CT and MRI are made to provide anatomical details of the adrenal mass, 
other imaging procedures can be made to target elements of adrenal function, enlightening 
metabolic pathways. For example, PET/CT may be a good method to evaluate adrenal 
masses, using radiopharmaceuticals targeted to various features of adrenocortical and 
medulla function. They have the potential to distinguish benign from malignant adrenal 
lesions, characterize the lesions, stage them in case of carcinoma and identify 
neuroendocrine tumours of chromaffin origin. PET/CT uses 18F-FDG [50] and 67Ga for 
malignant tumours [51]. Hydroxyephedrine-PET [52] may be useful to detect chromaffin 
tissue lesions. Besides this, scintigraphies may also be made that include 131I-6-
iodomethylnorcholesterol for cortical adenomas [53] and 123I-metaiodobenzylguanidine 
(MIBG) [53], for medullary chromaffin tissue lesions, including pheochromocytomas and 
ganglioneuromas [54]. 131I-6-iodomethylnorcholesterol (NP-59), is a radiotracer that is 
selectively taken up in the adrenal cortex, accumulating bilaterally in the normal adrenal 
glands and unilaterally in case of a hormonally active adenoma or carcinoma [55].  
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Regarding our patient, after uncertain CT and MRI scans, a MIBG scintigraphy was made 
that did not report abnormal hyperfixation zones. This exam was made to rule out 
pheochromocytoma [56]. In summary, the imaging procedures did not conclude any 
undoubtful diagnosis. Many patients still go to recurrent imaging scans and probably still 
do adrenalectomies that are not evidence-based necessary. However, in our clinical case, 
since the laboratorial work showed hormonal hyperfunction of the adrenal, 
adrenalectomy was evidence-based regardless of the imaging procedures.  
Although the probability was low (normal laboratory and MIBG scintigraphy), since the 
diagnosis of pheochromocytoma could not be completely ruled-out (suspect CT and 
MRI), left adrenalectomy was performed with pre-operative preparation for this 
condition. 
Several studies have reported that adrenalectomy is more beneficial than conservative 
management in patients presenting subclinical Cushing syndrome in an incidentaloma 
context, allowing remission of its co-morbidities [57]. That is, indeed, what happened to 
our patient, improving most of the laboratory hormonal alterations, improving arterial 
blood pressure values and glycemic control, reducing antihypertensive, oral 
antihyperglycemic agents and insulin need, improving body mass index and quality of 
life.  
Anatomopathological examination revealed that the lesion was an adrenal adenoma with 
pigment compatible with neuromelanin and foci of oncocytic cells. Several factors are 
considered for determining the malignancy nature of adrenal cortical tumours, such as 
tumour size, presence of necrosis, nodularity, and Weiss criterion (considered the 
standard). 9 parameters are evaluated: high nuclear grade, mitotic rate >5 per 50 HPF, 
atypical mitotic figures, eosinophilic tumour cells (≥75% of tumour), diffuse architecture 
(≥33% of tumour), necrosis, venous invasion (smooth muscle in wall), sinusoidal 
invasion (no smooth muscle in wall) and capsular invasion [58, 59].  The presence of 3 
or more of the nine criteria is suggestive of an adrenal cortical carcinoma, while two or 
less would be more evocative of an adenoma. So, according to these criteria, the mass 
was considered an adenoma.  
Since the lesion had a black colouring due to what was considered as neuromelanin 
pigment, it was designated as “black adenoma”. The term “pigment” refers to the different 
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colouring matter in the cell or tissue depositions and frequently are granules or 
cytoplasmic inclusions. The precise nature of the pigment is not always identifiable 
without complete histochemical characterization or electron microscopy and their 
identification not only helps in its correct diagnosis, but also provides important 
prognostic information. The main sources of tumour pigmentation are melanin or 
lipofuscin nodules, primary or secondary melanoma, haemangioma or adrenal 
myelolipoma. Lipofuscin, the main pigment found in cortical adrenal adenomas, is brown 
and develops inside of granules of senescent epithelial cells or in cells in degenerative 
altered cells (known as brown atrophy). The function of neuromelanin has yet to be sorted 
out. This substance is perceived as a waste product of catecholamine metabolism (data in 
vitro indicate that neuromelanin pigment is formed from the excess cytosolic 
catecholamine not accumulated into synaptic vesicles), and is indistinguishable from 
lipofuscin in its ultrastructure [60].  While the presence of lipofuscin in adrenal tumours 
is very common, interestingly, neuromelanin is not. There is a study that reaffirms that 
the presence of neuromelanin implies necessarily that catechol precursors were present in 
the pigmented cells, so they could be oxidized and polymerized to produce this pigment 
[61]. So, it is important to distinguish neuromelanin and lipofuscin pigments from 
melanin, since the latter is frequently present in primary and secondary malignancies, and 
the first ones are more often present in benign lesions [62]. There are some studies 
concluding that, in very rare cases, adrenal adenomas could be a source of 
catecholamines, eventually explaining some symptomatology of the patient, which was 
suggestive of pheochromocytoma, whose clinical presentation could be attributable to the 
presence of epinephrine noneccentric granules [63]. Alternatively, some studies have 
raised the possibility of a mass effect of the cortical tumour resulting in adrenal medullary 
hyperplasia [64, 65], the adrenal tumour itself can trigger the adrenal medulla to secrete 
catecholamines even without hyperplasia [66]. Adenomas are usually negative for S-100 
and HMB45 markers, positive low-molecular-weight keratins, limited and small-sized, 
measuring less than 5 cm [67]. Carcinomas are usually bigger in size and melanomas are 
positive Melan-A, HMB45 and S-100 [68]. Therefore, immunohistochemical analysis 
and electron microscopy can elucidate the true biphasic nature of these tumours.  
Besides the neuromelanin pigment described, oncocytic foci was also mentioned in the 
histopathological examination. Oncocytic cells are large epithelial cells with a deeply 
eosinophilic, granular cytoplasm. Oncocytic tumours, also designated as oncocytomas, 
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can also be found as adrenal incidentalomas. 75% are benign and 31% are associated with 
Cushing syndrome, virilizing syndrome or clinical features of pheochromocytoma [70]. 
Histopathologically, these tumours present a granular eosinophilic cytoplasm and 
numerous mitochondria. The salivary gland, kidney, thyroid, parathyroid and hypophysis 
are the main organs in which oncocytomas develop, but cases have been reported in the 
adrenal glands [71]. Usually, they have a considerable tumour size (8,5 cm in length), 
round, well- circumscribed, encapsulated, solid with possible areas of necrosis and/or 
haemorrhage that correspond  to brown areas [72]. No decisive features can discriminate 
benign from malignant adrenal oncocytic neoplasm on imaging scans, lacking clarity 
[73]. In fact, this agrees with the findings in the present case. However, absence of 
mitosis, tumour necrosis or vascular invasion helps to exclude the possibility of 
malignancy features [74].  This association, that is to say, neuromelanin pigments co-
existing with oncocytic foci of cells in the adrenal gland, is extremely rare and we found 
no case reported in literature [69].  
In the presence of a suspicious nodule, only microscopic criteria are able to determine a 
precise histology description and clinical behaviour, so adrenalectomy is the standard 
treatment, being laparoscopy the most diffuse approach [75]. 
In conclusion, this communication describes an extremely rare case of adrenal black 
adenoma with a clinical presentation mimicking pheochromocytoma and associated with 
a subclinical Cushing syndrome suggested by increased values cortisol, findings which 
posed some diagnostic dilemma pre-operatively. Therefore, we must reaffirm the 
relevance of the biochemical assessment in any patient with an adrenal mass, aside from 
any clinical symptoms and signs. It also shows the need for the development of new 
methods of study concerning the adrenal gland, since in this patient, CT and MRI were 
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 Table 1: Pre-operative and postoperative biochemical evaluation in the presented case. Surgery 
day was 16/03/2012.   





















Sodium (133–145 mmol/l) 143 N 141 142 141 
Potassium (3.3–5.1 mmol/l) 4,5 N 4,1 4,4 4,8 
Fasting glycemia (mg/dL) 335 106 147 123 130 
HbA1c (%) 9,7 7,4  6,9 7 
ACTH (6–50 pg/ml) <5 24 9 81 55 
Cortisol (6.7–22.6 μg/dl) 19 5,1 1,1 15 21,5 
Cortisol after low-dose DST test (normal 
suppression <1.8 μg/dl) 
23     
Renin in orthostatic position (4.4 -46.1 
µUI/mL) 
6,50   13  
Aldosterone  
(orthostasis:   97 - 626; decubitus:  42 - 202 
pg/mL)   
310,2  65,0  165,3  
DHEA-S (94.0–246μg/dl) < 15 <15 <15 <15 9 
24-h urinary free cortisol (55.5-286 
µg/24 h) 
456 76 206  68 
Urinary creatinine (600-1800 mg/24h).   456,6 405,0  556,7 610 
Urinary free cortisol µg/g-creatinine 1000 187   111 
Urinary aldosterone (2.8 - 30 µg/24hrs) 6.9 7.3 16.7   
24-h urinary norepinephrine (15-80 
µg/24h) 
29     
24-h urinary epinephrine (0-20 µg/24h) 33     
Normetanephrine-sulfate (44-540 µg/24h) 149,3     
Metanephrine-sulfate (26-230 µg/24h) 110,9     
Vanillylmandelic acid (1.8-6.7 mg/ 24h) 8,1     
5-Hydroxyindoleacetic Acid (0.7-8.2 
mg/24h) 











% OF HIGH 
DIASTOLIC BP 
Daytime 150 100% 78 11% 
Nightime 146 100% 75 86% 
Total 149  78  
 
 Table 2: 24-hours ambulatory blood pressure monitoring in mmHg (under nifedipine).  
 
